Anti-interleukin-2 receptor monoclonal antibody 33B3-1

Drug Profile

Anti-interleukin-2 receptor monoclonal antibody 33B3-1

Alternative Names: 33B3.1; Anti-CD25 monoclonal antibody 33B3.1; Interleukin-2 receptor monoclonal antibody 33B3.1

Latest Information Update: 05 Jul 1999

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Immunotech
  • Developer Immunotech; Nonindustrial source; sanofi pasteur
  • Class Monoclonal antibodies
  • Mechanism of Action Interleukin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Transplant rejection

Most Recent Events

  • 05 Jul 1999 No-Development-Reported for Transplant rejection in France (IV-infusion)
  • 18 Mar 1996 New profile
  • 18 Mar 1996 Phase-II clinical trials for Transplant rejection in France (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top